Skip to main content

Table 4 Predictors of 90-day mortality in the first 90 days on univariate and multivariate Competing Risk (liver transplant as the competing risk for mortality) analysis

From: Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation

 

Univariate

Multivariate

Sub-Hazard Ratio

(95% CI)

P value

Sub-Hazard Ratio

(95% CI)

P value

MELD

1.2 (1.1–1.3)

<.001

1.1 (1.02–1.15)

.008

Mean arterial pressure (mmHg)

0.93 (0.89–0.97)

<.001

0.95 (0.9–0.99)

.03

NSBB use

0.35 (0.12–1.02)

.05

0.29 (.09–.95)

.04

AKI (≥stage 2) within 90 days

11 (4.7–25.6)

<.001

4.4 (1.3–15.4)

.02

Child Pugh Score

1.22 (0.99–1.5)

.05

  

Gender (male)

2.6 (0.9–7.8)

.09

  
  1. Factors not predictive of 90-day mortality included; Age, body mass index, race, etiology of liver disease (hepatitis C, alcoholic or non-alcoholic fatty liver disease), serum albumin and serum sodium or prophylactic antibiotics. Stage 1 AKI was not associated with 90-day mortality and the analysis of AKI within 90-days was restricted to patients with AKI ≥ stage 2
  2. The results of the final model did not differ when including hospitalization for acute kidney injury prior to liver transplant evaluation
  3. Abbreviations: AKI acute kidney injury, MELD model for end-stage liver disease, NSBB non-selective beta blockers